AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Open original sourceLoading market dashboard
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Open original source